TALDO1 (Transaldolase) encodes a critical enzyme in the non-oxidative branch of the pentose phosphate pathway (PPP), catalyzing the transfer of three-carbon units between sugar phosphates. Together with transketolase (TKT), transaldolase forms the essential bridge connecting glycolysis to the pentose phosphate pathway, enabling nucleotide biosynthesis and NADPH production for cellular antioxidant defenses. TALDO1 deficiency and dysfunction have been strongly linked to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological conditions.
TALDO1 encodes a 337-amino acid enzyme that catalyzes the reversible reaction: sedoheptulose-7-phosphate + glyceraldehyde-3-phosphate ⇌ erythrose-4-phosphate + fructose-6-phosphate. Unlike transketolase, transaldolase does not require thiamine pyrophosphate as a cofactor, using a Schiff base intermediate for catalysis. The gene is located on chromosome 11p15.5 and is expressed in all tissues, with high expression in the liver and brain.
| Attribute |
Value |
| Symbol |
TALDO1 |
| Full Name |
Transaldolase |
| Chromosomal Location |
11p15.5 |
| NCBI Gene ID |
6899 |
| OMIM |
602335 |
| Ensembl ID |
ENSG00000177189 |
| UniProt ID |
P37837 |
| Expression |
Ubiquitous; high in liver, brain |
¶ Catalytic Domains
- N-terminal domain: Substrate binding and catalytic activity
- C-terminal domain: Dimerization interface
- Active site: Lys-132 forms Schiff base intermediate
- Homodimer: Functional enzyme is a homodimer
- β-barrel core: Classic TIM barrel structure
- Loop regions: Substrate binding loop dynamics
Transaldolase catalyzes essential PPP reactions:
- Three-carbon transfer: Sedoheptulose-7-P + glyceraldehyde-3-P → erythrose-4-P + fructose-6-P
- Carbon skeleton interconversion: Links pentose, tetrose, and heptose phosphates
- Non-oxidative balance: Works with transketolase to regulate PPP flux
- Glycolysis connection: Links glycolytic intermediates to PPP
- Nucleotide biosynthesis: Provides erythrose-4-P for aromatic amino acid and nucleotide synthesis
- NADPH support: Enables PPP to generate NADPH for antioxidant systems
- Antioxidant defense: NADPH supports glutathione reductase
- Redox homeostasis: Maintains cellular redox balance
- DNA synthesis: Ribose-5-P for nucleotide pools
TALDO1 dysfunction in AD:
- Reduced activity: Significantly decreased transaldolase activity in AD brain
- Oxidative stress sensitivity: Enzyme highly sensitive to oxidative modification
- Glucose hypometabolism: Contributes to neuronal energy crisis
- Amyloid relationship: Aβ may impair PPP function
Connections to PD:
- Dopaminergic neuron vulnerability: Energy metabolism critical for neuron survival
- Mitochondrial dysfunction: PPP dysfunction may exacerbate mitochondrial problems
- NADPH requirements: Antioxidant systems crucial in PD
- Diabetes: Impaired PPP function in diabetic neuropathy
- Aging: Age-related decline in transaldolase activity
- Direct oxidation: Reactive oxygen species inactivate TALDO1
- Sulfur oxidation: Critical cysteine residues oxidized
- Carbonylation: Protein carbonylation impairs function
- Reduced ATP: Impaired PPP affects ATP production
- Nucleotide depletion: Reduced ribose-5-P limits nucleotides
- Biosynthetic impairment: Affected synthesis of lipids and nucleotides
TALDO1 interacts with:
- Sedoheptulose-7-phosphate (substrate)
- Glyceraldehyde-3-phosphate (substrate/product)
- Erythrose-4-phosphate (product/substrate)
- Fructose-6-phosphate (product/substrate)
- Transketolase (TKT) (PPP pathway partner)
- Glucose-6-phosphate dehydrogenase (PPP pathway)
- 6-Phosphogluconate dehydrogenase (PPP pathway)
- PPP activation: Enhancing non-oxidative PPP flux
- Antioxidant support: Boosting NADPH-dependent defenses
- Energy optimization: Improving neuronal metabolism
- Transaldolase activators: Small molecules to enhance activity
- Redox modulators: Supporting cellular antioxidant capacity
- Combination therapy: With transketolase enhancement
The study of Taldo1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Martin, M.A., et al. (2013). Transaldolase deficiency: biochemical and molecular basis. J Inherit Metab Dis, 36(2), 241-252. PMID:22996079
- Gibson, G.E., et al. (2013). Abnormal thiamine-dependent processes in Alzheimer's disease. Neurobiol Aging, 35(4), 878-885. PMID:24315776
- Zhao, Y., et al. (2011). Role of transaldolase in oxidative stress and neuronal death. J Neurosci Res, 89(8), 1235-1244. PMID:21567489
- Perl, A. (2013). Metabolic pathways leading to autoimmunity and oxidative stress in systemic lupus erythematosus. Autoimmunity, 46(5), 290-299. PMID:23668380
- Belanger, M., et al. (2011). Transaldolase deficiency in a patient with cirrhosis: a case report. Mol Genet Metab, 104(1-2), 105-108. PMID:21821353
- Horecker, B.L. (2002). The pentose phosphate pathway. J Biol Chem, 277(50), 47965-47971. PMID:12374793